A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Victoza (liraglutide [rDNA origin]) Injection: REMS – Risk of Thyroid C-cell Tumors, Acute Pancreatitis. According to the Food & Drug Administration FDA’s MedWatch:
Reminder: Victoza not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.
For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Victoza (liraglutide [rDNA origin]) Injection: REMS – Risk of Thyroid C-cell Tumors, Acute Pancreatitis.
To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.
If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.